SCHEDULE: Armistice Capital Dumps Artelo Biosciences Stake

Armistice Capital, LLC and Steven Boyd have reported a 0.0% beneficial ownership of Artelo Biosciences, Inc. common stock, indicating a full divestment.

Summary

• Armistice Capital, LLC and Steven Boyd have filed an amendment to their Schedule 13G, reporting a 0.0% beneficial ownership of Artelo Biosciences, Inc. common stock as of June 30, 2026.
• This filing indicates that both Armistice Capital, LLC and Steven Boyd no longer hold any shares in Artelo Biosciences, Inc.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which was the direct holder of the shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.
• The Master Fund disclaims beneficial ownership due to the Investment Management Agreement with Armistice Capital.
• The filing is an amendment to a previous filing, reflecting a change in ownership status.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the complete divestment of shares, indicating a lack of confidence or strategic shift away from the company.

Negatives

• Armistice Capital, LLC and Steven Boyd have zero shares beneficially owned, indicating a complete exit from their investment in Artelo Biosciences, Inc.
• The filing signifies a complete lack of confidence or a strategic decision to move away from Artelo Biosciences, Inc. by a significant former holder.

Future Outlook

No forward-looking statements or guidance are present in this filing, as it solely pertains to ownership changes.

Management Comments

• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.
• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.

Industry Context

StockSavvy.ai notes that significant divestments by institutional investors, as indicated by this Schedule 13G filing, can signal a lack of confidence in a company's future prospects or a strategic reallocation of capital, potentially impacting market perception and share price.

Stakeholder Impact

• Shareholders may view this divestment by a former significant holder as a negative signal, potentially impacting share price and investor confidence.
• The market may interpret this as a lack of faith in Artelo Biosciences' future performance or strategy.

Key Dates

Recommendation

The complete divestment by Armistice Capital, a former significant holder, suggests a strong negative view on the company's future prospects, prompting a sell recommendation.

Keywords

Artelo Biosciences, Armistice Capital, Schedule 13G, Ownership Change, Divestment, Beneficial Ownership